New hemophilia drug hympavzi under safety watch
NCT ID NCT07161687
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 32 times
Summary
This study is checking the safety of the drug Hympavzi in 50 people with hemophilia A or B who do not have inhibitors. Researchers are tracking any side effects that may be related to the drug. The goal is to see how safe Hympavzi is when used in everyday medical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A OR B are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.